[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368745-105":59,"doc-detail-368745-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dual-loaded-niosome-dendrimer-nanoplatform-enhances-tirapazamine-delivery-to-hypoxic-breast-cancer-cells","Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells","","Breast cancer remains a leading cause of morbidity and requires strategies that reduce recurrence and mortality, especially against hypoxic, therapy-resistant tumor regions. This study develops a dual nanoparticle system using niosomes containing PAMAM/Tirapazamine (N@P/T), and evaluates efficacy through in silico analyses and experiments. Molecular docking and protein–protein interaction network analysis identifies HIF1A as a central TPZ target, and the formulation shows ~200 nm size, −4 mV zeta potential, and spherical morphology. N@P/T improves cytotoxicity and apoptosis versus P/T and free TPZ, increases cellular uptake above 90% within 4 h, and demonstrates superior tumor spheroid penetration under hypoxia, supporting its potential for breast cancer treatment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dual-loaded-niosome-dendrimer-nanoplatform-enhances-tirapazamine-delivery-to-hypoxic-breast-cancer-cells/368745/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dual-loaded-niosome-dendrimer-nanoplatform-enhances-tirapazamine-delivery-to-hypoxic-breast-cancer-cells/368745.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of developing the dual-loaded niosome-dendrimer nanoplatform (N@P/T)?","Question",{"text":113,"@type":114},"The goal is to improve Tirapazamine delivery and activity specifically in hypoxic breast cancer cells, where conventional therapies and delivery are less effective.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study identify the key molecular target for Tirapazamine (TPZ)?",{"text":118,"@type":114},"Molecular docking and protein–protein interaction network analysis identify HIF1A as a central target, revealing high-confidence binding interactions with cancer-related pathways.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence shows N@P/T is more effective than P/T and free TPZ?",{"text":122,"@type":114},"MTT results show a much lower IC50 for N@P/T (14.14 μM) and apoptosis assays demonstrate higher apoptosis promotion (65.33%) compared with P/T and free TPZ.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368745,1791090679,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells  \nMasoumeh Kaveh Zenjanab, Aysan Salemi, Abolfazl Doustmihan, SajjadAlimohammadvand & Rana Jahanban Esfahlan􀀍  \nBreast cancer (BC) is one of the most common cancers in women, requiring comprehensive treatment strategies to reduce disease burden and costs. In this study, we developed an innovative dual nanoparticle system based on niosome containing PAMAM/Tirapazamine (N@P/T), and studied its efficacy combining in silico and experimental validation. Molecular docking and protein–protein interaction network analysis identified HIF1A as a central target forTirapazamine (TPZ), revealing multiple high-confidence binding sites and interactions with key cancer-related pathways. Our synthesized N@P/T system using the thin film hydration method showed a size of ~ 200 nm, a zeta potential of − 4 mV, and a spherical morphology. Further, MTT results demonstrated that N@P/T significantly enhances anti-cancer effects compared to P/T and free TPZ, exhibiting the lowest IC50 value of 14.14 μM, which indicates superior cytotoxic efficiency compared to P/T (IC50 = 71.37 μM) and free TPZ (IC50 = 143.3 μM) . Annexin-V FITC/Pi double staining showed enhanced apoptosis-promoting effects of P/T (44.28%) and N@P/T (65.33%), partially via affecting expression levels of BCL2, caspase3 and BAX. The uptake assay revealed substantial internalization of N@P/T over 90% by 4h, while realtime PCR validated the HIF1A as a target for TPZ under hypoxia-stimulated condition. Furthermore, the spheroid size test demonstrates the superior penetration capability of N@P/T, leading to significant alterations in tumor spheroid size and morphology. Our integrated computational and experimental approach demonstrates that N@P/T effectively targets hypoxic cancer cells through specific molecular interactions, offering a promising strategy for BC treatment.  \nKeywords Niosome, Tirapazamin, PAMAM G5, Drug delivery, Cancer therapy  \nThe most common cancer in women is breast cancer (BC). While most BC cases are benign and can be treated with surgery, 25% have a latent, insidious nature that causes them to grow slowly but spread rapidly. Current treatments significantly slow the growth of the tumors, but they recur, resulting in high mortality rates1,2. According to recent data, 40% of BC patients die from metastasis, even when they receive standard treatment. The essential characteristic of triple-negative BC is its propensity for metastasis, which has a very complicated mechanism3–5. In healthy human cells, the release and consumption of oxygen are strictly regulated. Hypoxia is caused by increased O2 consumption resulting from enhanced cancer cell proliferation. Cancer cells are characterized by dysregulated cell proliferation and physiologically abnormal blood vessels due to extreme hypoxia6,7. Hypoxia makes traditional cancer treatments, such as prevalent chemotherapy drugs, ineffective and also hamper medication delivery. Because the hypoxic cells are located deep in the center of the tumor, beyond blood vessels, they cannot be reached by NPs or by therapies that are routinely administered8,9. To overcome these problems, drugs that can destroy cancer cells and NPs that penetrate the deep layer of cancer cells can be deployed10.  \nTirapazamine (TPZ; SR-4233), which acts under hypoxic conditions, is one of the clinical small molecule prodrugs against tumor hypoxia. Under hypoxia, TPZ is activated to form an extremely toxic free radical that damages DNA and eventually kills cells11. The harmful free radicals reoxidize to their inactive form when oxygen is present. TPZ exhibits a higher cytotoxic effect in the hypoxic regions of tumors due to its hypoxia-selective nature12. It is shown that TPZ has a hypoxia-selective effect in both in vitro and in vivo surveys. Research has  \nDepartment of Medi","cbCaiuvRRFzdZgAi","https://ap.wps.com/l/cbCaiuvRRFzdZgAi","pdf",3969429,18,"English","# Background and rationale\n## Hypoxia in breast cancer and limitations of existing therapies\n## Tirapazamine as a hypoxia-activated prodrug\n# Computational strategy for mechanism insight\n## Molecular docking and protein–protein interaction network analysis\n## Targeting HIF1A and hypoxia-related pathways\n# Nanoplatform design and characterization\n## N@P/T formulation via thin film hydration\n## Physicochemical properties and morphology\n# Biological evaluation\n## Cytotoxicity (MTT) and IC50 comparison\n## Apoptosis assays (Annexin-V FITC/Pi) and gene/protein effects\n## Cellular uptake and hypoxia-specific target validation (realtime PCR)\n## Spheroid penetration and morphology effects\n# Overall conclusion","[{\"question\":\"What is the purpose of developing the dual-loaded niosome-dendrimer nanoplatform (N@P/T)?\",\"answer\":\"The goal is to improve Tirapazamine delivery and activity specifically in hypoxic breast cancer cells, where conventional therapies and delivery are less effective.\"},{\"question\":\"How does the study identify the key molecular target for Tirapazamine (TPZ)?\",\"answer\":\"Molecular docking and protein–protein interaction network analysis identify HIF1A as a central target, revealing high-confidence binding interactions with cancer-related pathways.\"},{\"question\":\"What evidence shows N@P/T is more effective than P/T and free TPZ?\",\"answer\":\"MTT results show a much lower IC50 for N@P/T (14.14 μM) and apoptosis assays demonstrate higher apoptosis promotion (65.33%) compared with P/T and free TPZ.\"}]","Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells | PDF",1790178302,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2179ee2a445707ab672637db4896055.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/990d54113e9f15fb08f30e09f0513b4f.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73aac7e607f2ddb99431a143211e1b17.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd8fbc206f22441efe48ef242db4ce1f.webp",980,1287]